Antiseizure medication discovery: Recent and future paradigm shifts

Autores
Talevi, Alan
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Despite the ever-increasing number of available options for the treatment of epilepsies and the remarkable advances on the understanding of their pathophysiology, the proportion of refractory patients has remained approximately unmodified during the last 100 years. How efficient are we translating positive outcomes from basic research to clinical trials and/or the clinical scenario? It is possible that fresh thinking and exploration of new paradigms are required to arrive at truly novel therapeutic solutions, as seemingly proven by recently approved first-in-class antiseizure medications and drug candidates undergoing late clinical trials. Here, the author discusses some approximations in line with the network pharmacology philosophy, which may result in highly innovative (and, hopefully, safer and/or more efficacious) medications for the control of seizures, as embodied with some recent examples in the field, namely tailored multi-target agents and low-affinity ligands.
Laboratorio de Investigación y Desarrollo de Bioactivos
Materia
Ciencias Exactas
Biología
disrupting innovation
drug discovery
epilepsy
innovation
low-affinity ligand
multi-target
multi-target drugs
network pharmacology
partial agonist
radical innovation
systems pharmacology
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-nd/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/155997
Acceder
id SEDICI_bee0c6602b051d9994b8c6f27a6b845d
oai_identifier_str oai:sedici.unlp.edu.ar:10915/155997
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling Antiseizure medication discovery: Recent and future paradigm shiftsTalevi, AlanCiencias ExactasBiologíadisrupting innovationdrug discoveryepilepsyinnovationlow-affinity ligandmulti-targetmulti-target drugsnetwork pharmacologypartial agonistradical innovationsystems pharmacologyDespite the ever-increasing number of available options for the treatment of epilepsies and the remarkable advances on the understanding of their pathophysiology, the proportion of refractory patients has remained approximately unmodified during the last 100 years. How efficient are we translating positive outcomes from basic research to clinical trials and/or the clinical scenario? It is possible that fresh thinking and exploration of new paradigms are required to arrive at truly novel therapeutic solutions, as seemingly proven by recently approved first-in-class antiseizure medications and drug candidates undergoing late clinical trials. Here, the author discusses some approximations in line with the network pharmacology philosophy, which may result in highly innovative (and, hopefully, safer and/or more efficacious) medications for the control of seizures, as embodied with some recent examples in the field, namely tailored multi-target agents and low-affinity ligands.Laboratorio de Investigación y Desarrollo de Bioactivos2022-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfS133-S141http://sedici.unlp.edu.ar/handle/10915/155997enginfo:eu-repo/semantics/altIdentifier/issn/2470-9239info:eu-repo/semantics/altIdentifier/doi/10.1002/epi4.12581info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-09-29T11:40:31Zoai:sedici.unlp.edu.ar:10915/155997Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-09-29 11:40:32.077SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Antiseizure medication discovery: Recent and future paradigm shifts
title Antiseizure medication discovery: Recent and future paradigm shifts
spellingShingle Antiseizure medication discovery: Recent and future paradigm shifts
Talevi, Alan
Ciencias Exactas
Biología
disrupting innovation
drug discovery
epilepsy
innovation
low-affinity ligand
multi-target
multi-target drugs
network pharmacology
partial agonist
radical innovation
systems pharmacology
title_short Antiseizure medication discovery: Recent and future paradigm shifts
title_full Antiseizure medication discovery: Recent and future paradigm shifts
title_fullStr Antiseizure medication discovery: Recent and future paradigm shifts
title_full_unstemmed Antiseizure medication discovery: Recent and future paradigm shifts
title_sort Antiseizure medication discovery: Recent and future paradigm shifts
dc.creator.none.fl_str_mv Talevi, Alan
author Talevi, Alan
author_facet Talevi, Alan
author_role author
dc.subject.none.fl_str_mv Ciencias Exactas
Biología
disrupting innovation
drug discovery
epilepsy
innovation
low-affinity ligand
multi-target
multi-target drugs
network pharmacology
partial agonist
radical innovation
systems pharmacology
topic Ciencias Exactas
Biología
disrupting innovation
drug discovery
epilepsy
innovation
low-affinity ligand
multi-target
multi-target drugs
network pharmacology
partial agonist
radical innovation
systems pharmacology
dc.description.none.fl_txt_mv Despite the ever-increasing number of available options for the treatment of epilepsies and the remarkable advances on the understanding of their pathophysiology, the proportion of refractory patients has remained approximately unmodified during the last 100 years. How efficient are we translating positive outcomes from basic research to clinical trials and/or the clinical scenario? It is possible that fresh thinking and exploration of new paradigms are required to arrive at truly novel therapeutic solutions, as seemingly proven by recently approved first-in-class antiseizure medications and drug candidates undergoing late clinical trials. Here, the author discusses some approximations in line with the network pharmacology philosophy, which may result in highly innovative (and, hopefully, safer and/or more efficacious) medications for the control of seizures, as embodied with some recent examples in the field, namely tailored multi-target agents and low-affinity ligands.
Laboratorio de Investigación y Desarrollo de Bioactivos
description Despite the ever-increasing number of available options for the treatment of epilepsies and the remarkable advances on the understanding of their pathophysiology, the proportion of refractory patients has remained approximately unmodified during the last 100 years. How efficient are we translating positive outcomes from basic research to clinical trials and/or the clinical scenario? It is possible that fresh thinking and exploration of new paradigms are required to arrive at truly novel therapeutic solutions, as seemingly proven by recently approved first-in-class antiseizure medications and drug candidates undergoing late clinical trials. Here, the author discusses some approximations in line with the network pharmacology philosophy, which may result in highly innovative (and, hopefully, safer and/or more efficacious) medications for the control of seizures, as embodied with some recent examples in the field, namely tailored multi-target agents and low-affinity ligands.
publishDate 2022
dc.date.none.fl_str_mv 2022-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/155997
url http://sedici.unlp.edu.ar/handle/10915/155997
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/2470-9239
info:eu-repo/semantics/altIdentifier/doi/10.1002/epi4.12581
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
dc.format.none.fl_str_mv application/pdf
S133-S141
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1844616278015213568
score 13.070432

Publicaciones similares